PROK · Why this verdict
Why ProKidney (PROK) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
PROK has beaten earnings in its last two reports, but extreme cash burn, declining revenue, a confirmed technical downtrend, and an analyst target flagged as implausible keep the quality-driven exit call in place.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company is burning cash at an extreme rate, with free cash flow at roughly -8844% of revenue and a deeply failing Rule of 40 score. Quality breakdown | Free cash flow margin should improve materially off its current extreme deficit over the next several quarters as the clinical-stage business scales revenue. | →Stable |
| CounterA clinical-stage biotech with minimal current revenue will mechanically show an extreme negative FCF-to-revenue ratio, which is a function of the small revenue denominator rather than an unusually alarming cash-burn rate in absolute terms. | ||
Revenue is declining modestly, down about 2%, adding to the fundamental quality concerns for this clinical-stage company. Growth breakdown | Revenue growth should turn positive, rising above 0% year-over-year, over the next several quarters if the underlying business is scaling. | →Stable |
| CounterRevenue at this stage of a clinical-stage biotech is typically incidental collaboration or grant income, and small declines in it carry little signal about the core drug-development thesis. | ||
The stock is in a confirmed technical downtrend, trading below its 200-day moving average with a sharply negative -4.4% monthly moving-average slope. Momentum breakdown | Price should reclaim and hold above the 200-day moving average if the downtrend is set to reverse over the next several months. | ↓Deteriorating |
| CounterClinical-stage biotech stocks can gap sharply higher on binary trial or regulatory news, making the confirmed downtrend label less predictive than for a typical operating company. | ||
The system flagged the raw analyst price target as implausible, at roughly 3.1 times the current price, and rejected it in favor of a technical target, reducing confidence in the sentiment-driven upside case. Bear case | A verified, plausible analyst target should emerge that is more closely aligned with the current price over the next couple of quarters. | →Stable |
| CounterA large gap between price and analyst target for a clinical-stage biotech can be genuine if a binary catalyst, such as a trial readout, is expected to reprice the stock sharply. | ||
The company has beaten earnings in both of its last two reported quarters with a positive average surprise, showing some recent execution strength. Earnings | The beat rate should remain at or above 50% over the next several reporting quarters if execution momentum continues. | →Stable |
| CounterBeats against deeply negative EPS estimates for a pre-revenue clinical-stage biotech mostly reflect modest cost variance and carry little predictive value for the underlying clinical thesis. | ||
The company is burning cash at an extreme rate, with free cash flow at roughly -8844% of revenue and a deeply failing Rule of 40 score.
→StableQuality breakdown
- Expectation
- Free cash flow margin should improve materially off its current extreme deficit over the next several quarters as the clinical-stage business scales revenue.
CounterA clinical-stage biotech with minimal current revenue will mechanically show an extreme negative FCF-to-revenue ratio, which is a function of the small revenue denominator rather than an unusually alarming cash-burn rate in absolute terms.
Revenue is declining modestly, down about 2%, adding to the fundamental quality concerns for this clinical-stage company.
→StableGrowth breakdown
- Expectation
- Revenue growth should turn positive, rising above 0% year-over-year, over the next several quarters if the underlying business is scaling.
CounterRevenue at this stage of a clinical-stage biotech is typically incidental collaboration or grant income, and small declines in it carry little signal about the core drug-development thesis.
The stock is in a confirmed technical downtrend, trading below its 200-day moving average with a sharply negative -4.4% monthly moving-average slope.
↓DeterioratingMomentum breakdown
- Expectation
- Price should reclaim and hold above the 200-day moving average if the downtrend is set to reverse over the next several months.
CounterClinical-stage biotech stocks can gap sharply higher on binary trial or regulatory news, making the confirmed downtrend label less predictive than for a typical operating company.
The system flagged the raw analyst price target as implausible, at roughly 3.1 times the current price, and rejected it in favor of a technical target, reducing confidence in the sentiment-driven upside case.
→StableBear case
- Expectation
- A verified, plausible analyst target should emerge that is more closely aligned with the current price over the next couple of quarters.
CounterA large gap between price and analyst target for a clinical-stage biotech can be genuine if a binary catalyst, such as a trial readout, is expected to reprice the stock sharply.
The company has beaten earnings in both of its last two reported quarters with a positive average surprise, showing some recent execution strength.
→StableEarnings
- Expectation
- The beat rate should remain at or above 50% over the next several reporting quarters if execution momentum continues.
CounterBeats against deeply negative EPS estimates for a pre-revenue clinical-stage biotech mostly reflect modest cost variance and carry little predictive value for the underlying clinical thesis.
Per-dimension breakdown
Quality
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 5.5 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -8844% of revenue
- ▸Rule of 40: -8846 (fail)
Growth
2.1/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 2.1 |
- ▸Declining revenue: -2%
Momentum
1.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 3.4 |
| OBV | 1.0 |
| MA position | 1.0 |
| Volume | 0.0 |
- ▸Capitulation risk (RSI 15, below 200MA)
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -5.0%/30d — confirmed downtrend
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 311%
Insider
6.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 8.3 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 2.8 |
| growth rank | 3.6 |
Technical
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.2 |
| support resistance | 9.5 |
| 52w position | 0.0 |
| gap | 6.0 |
Risk (lower is worse)
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.6 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 0.0 |
| beta | 4.4 |
| debt equity | 9.9 |
- ▸Elevated put/call: 100.00
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 5.9 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:19d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:1.7<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (1)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
14.3%
Sizing output
AVOID
SetupFalling Knife — Death cross, below all MAs, RSI 15, MACD bearish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -79% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 1.7<4.5 outcome against Insider at 6.8 and asymmetric R:R of 0.00.
The strongest dimensions are Insider at 6.8, Sentiment at 6.6, and Catalyst at 6.5; the weakest are Momentum at 1.7, Growth at 2.1, and Risk (lower is worse) at 3.0. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Extreme Cash Burn Quality Risk
Trip ifFree cash flow margin rises above -100% of revenue from the current -8844%, indicating a material reduction in cash burn.
- P2Declining Revenue Trend
Trip ifRevenue growth rises above 0% YoY from the current -2% decline, turning positive.
- P3Confirmed Technical Downtrend
Trip ifPrice rises above the 200-day moving average and stays above it for 2 consecutive weeks, reversing the confirmed downtrend.
- P4Implausible Analyst Target Flag
Trip ifA verified analyst target rises to within 2 times the current $2.03 price, replacing the rejected $6.25 implausible target.
- P5Consistent Earnings Beats
Trip ifQuarterly EPS beat rate falls below 50% over the next 4 quarters, ending the current 2-of-2 beat streak.